Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.